GHRP-2 vs MK-677

GHRP-2 (pralmorelin) and MK-677 (ibutamoren) are both growth hormone secretagogues that activate the ghrelin receptor (GHS-R1a), but they represent fundamentally different classes of research compounds. GHRP-2 is a synthetic hexapeptide requiring injection, with a rapid, potent, and transient effect on GH release. MK-677 is a non-peptide, orally bioavailable compound that produces sustained elevations in GH and IGF-1 over 24 hours. Their distinct pharmacokinetic profiles and routes of administration lead to different research applications and safety considerations. This comparison examines their mechanisms, evidence bases, dosing protocols, and safety profiles to help researchers understand key differences and overlaps.

GHRP-2 (pralmorelin) is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817.97 g/mol) that acts as a potent, dose-dependent growth hormone secretagogue via the ghrelin receptor (GHS-R). It is considered more potent than GHRP-6 and induces less appetite stimulation, making it a refined tool for studying GH pulse dynamics. Notably, GHRP-2 has regulatory approval in Japan as a diagnostic agent for GH deficiency (pralmorelin), and clinical studies in GH-deficient children over 8–24 months have demonstrated maintained efficacy on growth velocity with a placebo-like safety profile at therapeutic doses. Research evidence includes controlled clinical trials supporting its diagnostic utility and long-term safety, though its use as a therapeutic agent remains limited to specific approved indications.

MK-677 (ibutamoren) is a potent, long-acting, orally-active, non-peptide ghrelin receptor (GHS-R1a) agonist that stimulates growth hormone release without requiring injection. Unlike injectable GH peptides such as GHRP-6 or Ipamorelin, MK-677 can be administered orally and maintains elevated GH and IGF-1 levels for up to 24 hours, providing a sustained anabolic signal. It has been investigated in several human clinical trials for conditions including GH deficiency, muscle wasting, bone density, and sleep quality. Research indicates improvements in lean body mass and sleep quality, but MK-677 is not FDA-approved for any indication. The evidence base includes randomized controlled trials, but outcomes are mixed regarding functional benefits, and concerns about metabolic effects (e.g., insulin sensitivity) remain a focus of ongoing investigation.

Both GHRP-2 and MK-677 are studied for their effects on body composition, particularly in contexts involving lean mass preservation or growth hormone-mediated anabolism. However, their research applications diverge beyond this overlap. GHRP-2 is primarily investigated for its role in GH pulse stimulation and as a diagnostic tool for GH deficiency, with no unique applications beyond body composition. In contrast, MK-677 has been explored in anti-aging research due to its sustained IGF-1 elevation and potential to counteract age-related declines in muscle and bone mass. Additionally, MK-677 is studied for sleep quality enhancement, likely mediated by ghrelin receptor agonism in the central nervous system. These differences reflect their distinct pharmacokinetic profiles and research priorities.

GHRP-2: In clinical trials, GHRP-2 has demonstrated a placebo-like safety profile at therapeutic doses. It may increase appetite, though to a lesser extent than GHRP-6, and can elevate cortisol and prolactin levels, again less pronounced than GHRP-6. Long-term studies in children show maintained safety over 8–24 months. MK-677: Common side effects include increased appetite (due to ghrelin agonism), water retention or mild edema, and transient muscle pain. Metabolic effects are a key concern: MK-677 may elevate fasting blood glucose and reduce insulin sensitivity in a dose-dependent manner, which is particularly relevant for research in diabetic or pre-diabetic models. Fatigue and lethargy have also been reported by some users. Researchers should consider these profiles when designing studies and interpreting metabolic outcomes.